Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial
Journal of the American Academy of Dermatology Feb 21, 2018
Yosipovitch G, et al. - In the treatment of chronic pruritus, the safety and effectiveness of the neurokinin 1 receptor (NK1R) antagonist serlopitant were evaluated by the experts. In cases of chronic pruritus, statistically notable reduction was caused by serlopitant 1 mg and 5 mg daily. These treatments were noted to be well tolerated.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
